Table 3

Change in biomarkers with anti-estrogenic treatment

Controls (n = 18)

All Cases (n = 23)

Postmenopausal Cases (n = 9)

Premenopausal Cases (n = 14)

Biomarker

Mean change¹

Mean change

p²

Mean change

p

Mean change

p

ER (H-score)³

-55.5 ± 22.2

-92.1 ± 23.7

0.21

-113.8 ± 26.2

0.07

-78.2 ± 35.4

0.62

PR (H-score)³

-38.8 ± 18.3

-110.1 ± 18.7

0.03

-169.2 ± 18.8

0.001

-72.1 ± 22.0

0.40

Ki-67⁴

-3.2 ± 1.7

-10.2 ± 1.8

0.007

-14.4 ± 3.6

0.013

-7.5 ± 1.6

0.037

CD68⁴

-0.06 ± 1.7

34.1 ± 8.3

<0.0001

29.4 ± 5.8

<0.0001

37.2 ± 13.2

0.002

caspase 3⁵

0.8 ± 0.7

0.1 ± 0.4

0.15

-0.1 ± 0.7

0.13

0.2 ± 0.5

0.33

¹Data shows mean increase (positive values) or mean decrease (negative values) in quantitative immunohistochemical staining between diagnostic core biopsy and surgical excision. Cases were treated with neoadjuvant anti-estrogenic therapy; controls did not undergo neoadjuvant therapy.

²Rank-sum test, controls as referent group.

³H-score is weighted measure of intensity and percentage of positive cells (see Methods).

⁴Percent of cells staining positive.

⁵Number of CD68-positive macrophages per high power field within DCIS ducts.

Chen et al. BMC Cancer 2009 9:285   doi:10.1186/1471-2407-9-285